Journals / Turkish Journal of Medical Sciences / 2022 / Cilt: 52 - Sayı: 1

Pleuroparenchymal fibroelastosis in systemic sclerosis-associated interstitial lung disease

Pages
83–88
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further studies are needed to elucidate the prognostic value of PPFE in SSc-ILD.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: To explore the frequency and clinical associations of radiologic pleuroparenchymal fibroelastosis (PPFE) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
📊
Key Findings & Data:Materials and methods: In this single-center retrospective study, high resolution computed tomography (HRCT) images of 105 patients with SSc-ILD were examined for the presence of PPFE.
💡
Conclusion & Impact:Further studies are needed to elucidate the prognostic value of PPFE in SSc-ILD.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: To explore the frequency and clinical associations of radiologic pleuroparenchymal fibroelastosis (PPFE) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Materials and methods: In this single-center retrospective study, high resolution computed tomography (HRCT) images of 105 patients with SSc-ILD were examined for the presence of PPFE. Demographic, clinical, laboratory, and pulmonary function test (PFT) data of patients with and without PPFE were compared. Results: PPFE was detected in 19 (18.1%) patients (‘definite PPFE’ in 13 and ‘consistent with PPFE’ in 6 patients). Patients with PPFE had higher age and longer disease duration than PPFE (-) patients (p < 0.05 for both). Radiologic usual interstitial pneumoniae (UIP) pattern was more frequent (26.3% vs. 4.7%, p = 0.01) and median force vital capacity (FVC) was lower in patients with PPFE (64% vs. 82%, p = 0.005). Spontaneous pneumothorax developed in one patient with PPFE. More deaths occured in PPFE (+) group during follow-up (31% vs. 11%, p = 0.04). Conclusion: PPFE on HRCT is not uncommon in SSc-ILD and is associated with radiologic UIP pattern and worse lung functions. Further studies are needed to elucidate the prognostic value of PPFE in SSc-ILD.

🔖

Cite This Article

BİLGİN, E., AKDOĞAN, A., SARI, A., ARMAĞAN, B., ÖNDER, Ö., ARIYÜREK, M., YARDIMCI, G. K., BÖLEK, E. Ç., FARİSOĞULLARI, B. (2022). Pleuroparenchymal fibroelastosis in systemic sclerosis-associated interstitial lung disease. Turkish Journal of Medical Sciences, Cilt: 52 - Sayı: 1, 83–88. https://ajindex.com/articles/609244

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Denton CP, Wells AU, Coghlan JG. Major lung complications of systemic sclerosis. Nature Reviews Rheumatology 2018;14(9):511-527. doi: 10.1038/s41584-018-0062-0 2. Khanna D, Nagaraja V, Tseng CH, Abtin F, Suh R et al. Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials. Arthritis Research & Therapy 2015;23; 17: 372. doi: 10.1186/s13075- 015-0872-2 3. Goldin JG, Lynch DA, Strollo DC, Suh RD, Schraufnagel DE et al. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest 2008; 134:358. doi: 10.1378/chest.07-2444 4. Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. American Journal of Respiratory and Critical Care Medicine 2002;165(12):1581-6. doi: 10.1164/ rccm.2106012 5. Cheng SK, Chuah KL. Pleuroparenchymal fibroelastosis of the lung: a review. Archives of Pathology & Laboratory Medicine 2016;140(8):849-53. doi: 10.5858/arpa.2015-0166-RS 6. Travis WD, Costabel U, Hansell DM, King ET, Lynch DA et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. American Journal of Respiratory and Critical Care Medicine 2013;188(6):733–748.doi: 10.1164/rccm.201308-1483ST 7. Nakatani T, Arai T, Kitaichi M, Akira M, Tachibana K. Pleuroparenchymal fibroelastosis from a consecutive database: a rare disease entity? European Respiratory Journal 2015;45(4):1183– 1186. doi: 10.1183/09031936.00214714 8. Bonifaz iM, Sverzellati N, Negri E, Jacob J, Egashira R et al. Pleuroparenchymal fibroelastosis in systemic sclerosis: prevalence and prognostic impact. European Respiratory Journal 2020;9;56(1):1902135. doi: 10.1183/13993003.02135- 2019 9. Bargagli E, Mazzei MA, Orlandi M, Gentili F, Bellisai F et al. Pleuroparenchymal fibroelastosis in patients affected by systemic sclerosis: What should the rheumatologist do? Medicine (Baltimore) 2019: 98(26):e16086. doi: 10.1097/ MD.0000000000016086 10. Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism c